SEATTLE, March 27 /PRNewswire/ -- Amnis Corporation, a manufacturer of advanced instrumentation for the life science research and diagnostics markets, announced today that it had closed its Series C round of financing. The round, originally targeted at $6 million, was significantly oversubscribed and closed with a total investment of $11.25 million. Joining the initial participants in the round were CVF, LLC, the venture capital arm of the Crown family of Chicago, and MedVenture Associates of Emeryville, California. Richard Robb from CVF and Annette Campbell-White from MedVenture Associates have joined the Amnis board of directors. The Company will use the proceeds from the Series C round to expand its commercial operations and to accelerate its strategic product development programs.
Amnis Corporation, headquartered in Seattle, WA, develops, manufactures and markets instrumentation for high speed imaging of cells in flow. Its flagship product, the ImageStream(R) cell analysis system, generates six high resolution microscopic images of cells as they flow through the instrument at rates up to 300 cells per second. The system is unique in its ability to image tens of thousands of cells in minutes without the need to make slides. The IDEAS(R) image analysis package, an integral part of the ImageStream system, is a highly sophisticated yet easy to use tool for processing hundreds of thousands of images at a time. IDEAS enables highly advanced research applications in hematology, immunology, oncology and provides a critical foundation for the company's clinical applications development.
"We were extremely gratified by the high level of interest in this final round of financing," said David Basiji, Ph.D., Amnis' President and CEO. "Both CVF and MedVentures are experienced investors who bring extensive operational and clinical expertise to the Amnis business leadership. These strengths will be extremely valuable as we expand our commercial operations, bring second- generation ImageStream technology to market, and develop highly advanced clinical applications in hematology and cancer diagnostics."
William Ortyn, Amnis' COO added. "We are rapidly expanding our production and service arms, as well as enhancing our sales and R&D capabilities. We will continue to operate Amnis as we have to date, with a high degree of efficiency and a tight focus on fulfilling the potential of our ImageStream technology in the life sciences."
Amnis CorporationCONTACT: David Basiji of Amnis Corporation, +1-206-374-7000
Web site: http://www.amnis.com/
